The earnings call presented a mixed picture for Organogenesis Holdings. While there were significant achievements in the Surgical & Sports Medicine segment and progress in strategic initiatives and CMS payment reforms, these were overshadowed by notable declines in Advanced Wound Care revenue, overall revenue, and profitability. The reduction in financial guidance and gross margin decline further contributed to a challenging outlook.

Company Guidance -

Q3 2025

During the Second Quarter 2025 Earnings Conference Call for Organogenesis Holdings, Inc., the company provided updated financial guidance and strategic insights. The company reported net product revenue of $100.8 million, a 23% decline year-over-year, with Advanced Wound Care products contributing $92.7 million, down 25%, and Surgical & Sports Medicine products contributing $8.1 million, up 16%. Gross profit was $73.1 million, representing 73% of net product revenue. The company adjusted its 2025 revenue guidance to a range of $480 million to $510 million, reflecting a potential year-over-year change of flat to an increase of 6%. Additionally, Organogenesis highlighted the anticipated impact of CMS's proposed Medicare physician fee schedule changes for 2026, which they believe will create a more level playing field and drive growth in their product portfolio, including PMA products like Apligraf and Dermagraft. The company remains focused on strategic expansions, such as the Smithfield biomanufacturing facility, and prepares for the potential launch of new products, including ReNu, by the end of the year.

Surgical & Sports Medicine Revenue Growth

Net product revenue from Surgical & Sports Medicine products for the second quarter was $8.1 million, up 16% year-over-year.

Strategic Expansion and Innovation

Expansion of biomanufacturing capabilities in Smithfield, Rhode Island and introduction of new products like FortiShield and reintroduction of PMA-approved products Dermagraft and TransCyte.

CMS Payment Reform Proposal

CMS proposed new payment approach for skin substitutes, potentially increasing reimbursement rates significantly, which is expected to benefit Organogenesis' products like Apligraf.

ReNu Program Progress

ReNu program on track for BLA submission by the end of 2025, with promising Phase III study results expected to address knee osteoarthritis in over 30 million Americans.

Operating Expense Reduction

Operating expenses for the second quarter decreased by $30.5 million or 21% year-over-year.

Organogenesis Holdings Inc (ORGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ORGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.09 / -	0.09	―	―	―
Aug 07, 2025	2025 (Q2)	-0.05 / -0.06	-0.13	51.54% (+0.07)	―
May 08, 2025	2025 (Q1)	-0.04 / -0.17	-0.015	-1033.33% (-0.16)	―
Feb 27, 2025	2024 (Q4)	-0.01 / 0.04	0.019	110.53% (+0.02)	―
Nov 12, 2024	2024 (Q3)	-0.02 / 0.09	0.036	150.00% (+0.05)	―
Aug 08, 2024	2024 (Q2)	<0.01 / -0.13	0.046	-382.61% (-0.18)	―
May 09, 2024	2024 (Q1)	-0.02 / -0.01	-0.003	-400.00% (-0.01)	―
Feb 29, 2024	2023 (Q4)	<0.01 / 0.02	0.071	-73.24% (-0.05)	―
Nov 09, 2023	2023 (Q3)	0.01 / 0.04	0.037	-2.70% (>-0.01)	―
Aug 09, 2023	2023 (Q2)	0.03 / 0.05	0.085	-45.88% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ORGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.52	$4.56	+0.88%
May 08, 2025	$5.34	$3.06	-42.70%
Feb 27, 2025	$3.07	$6.21	+102.28%
Nov 12, 2024	$3.45	$4.43	+28.41%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Organogenesis Holdings Inc (ORGO) report earnings?

Organogenesis Holdings Inc (ORGO) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Organogenesis Holdings Inc (ORGO) earnings time?

Organogenesis Holdings Inc (ORGO) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ORGO EPS forecast?

ORGO EPS forecast for the fiscal quarter 2025 (Q3) is 0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing